Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Theravance Biopharma (NASDAQ: TBPH) is set to disclose its Q4 2021 and full year 2021 financial results on February 23, 2022, after market close. A conference call will follow at 5:00 PM ET. The company specializes in respiratory medicines and has developed the FDA-approved YUPELRI for COPD patients. It also has economic interests related to Glaxo Group Limited's programs, notably TRELEGY. The financial results and business updates will be crucial for investors monitoring TBPH's growth trajectory.
- FDA-approved YUPELRI for chronic obstructive pulmonary disease (COPD).
- Economic interest in potential future payments from GSK regarding TRELEGY.
- None.
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday, February 23, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.
Conference Call Information
To participate in the live call by telephone, please dial (855) 296-9648 from the US or (920) 663-6266 for international callers, using the confirmation code 7456139. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Presentations and Events.
A replay of the conference call will be available on Theravance Biopharma's website for 30 days through March 25, 2022. An audio replay will also be available through 8:00 pm ET on March 2, 2022 by dialing (855) 859-2056 from the US, or (404) 537-3406 for international callers, and then entering confirmation code 7456139.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-23-2022-301478234.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma report its Q4 2021 financial results?
What time is the Theravance Biopharma conference call scheduled?
What is the focus of Theravance Biopharma's business?
What is YUPELRI and for what condition is it approved?
What economic interests does Theravance Biopharma have related to GSK?
